Developed by leading oncologists, our proprietary biomarker technologies offer you unparalleled support for clinical decision-making.
By Experts For Experts
OCB was founded by internationally renowned University of Oxford cancer professors, Nick La Thangue and David Kerr to revolutionise cancer clinical decision medicine using ground-breaking biomarker technology.
Current tests are focussed on colorectal cancer diagnosis, management and treatment with wide application in many other cancers.
BioMarker Technologies
Reduces risk of chemotherapy toxicity
Identifies whether your patient is at risk of capecitabine toxicity. Enables a clinically rotreatment decisions and reduces the risk of severe adverse effects with ToxNav.
Improve your patients’ quality of life and reduce treatment costs. Proven to be clinically effective.
Guide chemotherapy usage using AI analysis of large clinical datasets
What if you could find out which of your patients are at low, intermediate or high risk of colorectal cancer relapse?
OncoProg uses innovative digital pathology and proprietary algorithms to create a risk profile for your patients and help inform your next clinical decision.
Identifies healthy individuals with a 5 fold higher risk of developing colorectal cancer
What if you could find out which of your patients are at low, intermediate or high risk of colorectal cancer relapse?
OncoProg uses innovative AI and gene analysis to create a risk profile for your patients and help inform your next clinical decision.
The future of precision cancer biomarkers
We are constantly developing our products to improve their performance and clinical relevance.
Read more about our product pipeline or contact our representatives today to find out how you can access our products and platforms.
